. Improving the efficacy of CYD-TDV or developing second-generation vaccine 66 candidates is essential to broaden the coverage for all vulnerable populations 4, 5, 6 . 67
68
The envelope (E) protein of DENV on the surface of viral particles is the major target of 69 neutralizing antibodies (NtAbs) 7, 8 . The ectodomain of the E protein contains three distinct 70 domains, EDI, EDII, and EDIII, which are connected by flexible hinges to allow rearrangement . The pr portion of the prM protein, positioned to cover the fusion loop (FL) peptide at 77 the distal end of each E protein, prevents premature fusion during the maturation process 12, 13 . 78 For DENV to become fully infectious, the pr molecule has to be removed by a cellular furin . Also, VLP vaccines present several advantages 98 since they are highly immunogenic, non-infectious, and accessible to quality control as well as 99 increased production capacity. In this study, we evaluated a mature form of a monovalent dengue 100 VLP for its ability to induce an enhanced immune response with broad neutralizing activity 101 against both homologous and heterologous dengue viruses from all four serotypes. 
Results

104
We theorized that the process of VLP maturation might be similar to that of dengue viral 105 particles so that VLP antigens would also induce prM-recognizing non-NtAbs. To overcome this (Fig. 1A ). An 120 additional mutation in the P3 residue from E to S of the CFAV P1-8 construct reduced the prM 121 signaling to 13.7% of that of imD2VLP. We thus named this construct with the replacement of 122 CFAV P1-8 plus the P3 E to S mutation as mD2VLP. The pr/M cleavage of this construct was 123 increased to nearly 90% (Fig. 1B) . The mD2VLP and imD2VLP, purified from plasmids antibodies, we used the same quantity of purified VLPs in the antigen-capture ELISA ( Fig. 2A) . vs. 1:6,381 for mD2VLP and imD2VLP, respectively) (Fig. 2B) . We also analyzed the 141 neutralizing ability of these sera against the four serotypes of DENV using a 50% antigen focus- , were all 214 well-exposed in VLPs without steric hindrance. 215 The preservation of neutralizing epitopes on the surface of VLPs is critical for efficient 217 production of broadly neutralizing antibody responses. We next investigated if a broad 218 neutralization response to mD2VLP immunization was due to the induction of antibodies with a 219 preference to bind at the E dimer epitopes preserved on the surface of mature VLP 18, 19 . The 220 splenocytes from mD2VLP-vaccinated mice were used to perform fusion and generate 221 hybridomas. Among all hybridomas screened, the reactivities of two representative MAbs were 222 measured by ELISA (Fig. 5A) . The results showed that DM8-6 is a serotype-specific MAb 223 reactive only with DENV-2; while MAb DM25-3 recognized all four serotypes of DENV. Next, 224 we tested the neutralizing activity of these two MAbs against four serotypes of DENV. DM8-6 225 showed good neutralizing activity against DENV-2 at a concentration of 0.037 μg/mL in , DM25-3 was tested for its binding activity to both mD2VLP 232 and imD2VLP using antigen-capture ELISA. MAb DM25-3 recognized mD2VLP very well, but 233 reacted poorly with imD2VLP (Fig. 5C) . Next, we performed site-directed mutagenesis on the . Fig. 4C shows that residue 101 is located at the touching point between EDII and EDIII of 240 the dimeric molecule. Since residue 101 is a critical residue in stabilizing E-protein dimers on 241 DENV virion, mutation on 101 would disrupt viral particle formation 26, 36 . However, mutation of 242 residue 101 on mD2VLP can still form particles (Fig S9) , which further support our cryoEM 243 model that the E:E protein interactions on VLP are loose. When the E:E protein interaction was 244 looser, residue 101 at the groove within the dimeric molecule was more exposed (64%) than on (Fig. 5D) , suggesting that DM25-3 could be an E-dimer inter-251 domain antibody whose binding footprint is sensitive to amino acid changes in the EDIII 252 domain. By comparing FRμNT 50 tests using murine antisera on both PL046 and PL046cEDIII 253 viruses, we found that anti-mD2VLP sera showed a greater difference in neutralizing activity 254 against PL046 and PL046cEDIII than did anti-imD2VLP sera, indicating a greater 255 conformational dependence for anti-mD2VLP-triggered neutralization (Fig. 5E ). onto the structure of mD2VLP, the binding footprints of these antibodies were highly 288 overlapping and formed a "neutralization-sensitive hotspot" on mD2VLP (Fig. S12) . Thus, the 289 underlying mechanisms of why mD2VLPs are able to stimulate an elevated and broader immune 290 response are based on the following: (1) epitope accessibility exposed at the grooves within E- Competing interests: All the authors declare that they have no competing interests. was determined using the two-tailed Mann-Whitney U test to account for non-normality of the transformed data. *, P <0.05; **, P <0.01; 510 ****, P <0.0001. by dark red, deem red and grey in the E dimer surface rendering. The groove located within E-dimer interface was outlined. (B) The 542 highly exposed residues (Δ%SASA >0.2) which were colored by dark red were shown in the surface rendered E-dimer. The residues 543 in E interacting with MAb 1A1D-2, 2D22 and EDE were in cyan spheres showing that they were highly exposed on the m2DVLP 544 surface. Importantly, the binding footprints of the three antibodies were highly overlapping with footprint of highly exposed residues 545 in m2DVLP, and formed a neutralization sensitive patch on m2DVLPs. The areas of the interacting epitopes are circled by black lines. 
